课题基金 / 基金详情

Identification of Bacterial Resistance Mechanisms to Antimicrobial Chemokines

Identification of Bacterial Resistance Mechanisms to Antimicrobial Chemokines
细菌对抗菌趋化因子的耐药机制的鉴定
批准号:
8367534
负责人:
David L. Erickson
金额:
$37.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-05-01 至 2016-04-30

项目摘要

项目成果

David L. Erickson的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Antimicrobial chemokines (AMCs) are understudied members of the family of host defense peptides, which together play an essential role in protecting a wide variety of organisms from bacterial infection. Understanding how AMCs recognize and bind to bacterial targets is key to understanding the basic mechanisms of the innate immune system, as well as designing new antimicrobial therapies that build on millions of years of co-evolution between pathogens and the innate immune system. This application tests the hypothesis that different bacteria are not uniformly affected by AMCs, and identifying bacterial proteins that modulate AMC susceptibility will uncover processes that could provide novel targets for antimicrobial therapy. Since differences in binding to AMCs could be a critical determinant of bacterial susceptibility, we have developed a flow cytometry based assay to measure AMC binding to bacterial cells. Aim 1 involves utilizing this assay to screen thousands of Yersinia transposon mutants to identify those with high AMC binding phenotypes compared to wild type bacteria. Genes associated with lipopolysaccharide biosynthesis appear to play a major role in AMC avoidance and resistance, and Aim 2 involves a detailed characterization of the contributions of these genes to AMC avoidance in both Y. pseudotuberculosis and Y. pestis. Aim 3 tests whether increases in AMC binding due to specific mutations correlate with increased sensitivity to killing by AMCs, as well as by other host defense peptides. Understanding how AMCs and other host defense peptides recognize and bind bacteria, as well as how bacteria evade the antimicrobial activity of host defense peptides, could lead to novel drug targets that enhance the innate immune system. The therapeutic use of AMCs to fight infections may be significantly enhanced by simultaneously targeting processes such as lipopolysaccharide biosynthesis that are required for resistance to these peptides. PUBLIC HEALTH RELEVANCE: This project involves determining how bacterial pathogens resist the body's innate immune defenses. These defenses include a family of peptides called antimicrobial chemokines. These peptides can kill bacteria directly, in addition to their other roles in the immune system. New treatments that interfere with bacterial defense mechanisms could render pathogens less able to cause disease.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1038/s41598-017-11334-6
发表时间: 2017-09-07
期刊: Scientific reports
影响因子: 4.6
作者: [Hoffman JM, Sullivan S, Wu E, Wilson E, Erickson DL]
通讯作者: Erickson DL
Investigating virulence functions of mastitis-associated Extraintestinal pathogenic Escherichia coli relevant to human disease
  • 批准号:
    10439133
  • 项目类别:
  • 资助金额:
    $37.88万
  • 财政年份:
    2022
  • 负责人:
    David L. Erickson
  • 依托单位:
海外基金